Loading market dashboard
DSS, Inc.
DSSConsumer CyclicalAMEXUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025.
ROCHESTER, N. Y. , April 15, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today issued the following letter to shareholders from the Interim CEO, Jason Grady, highlighting the Company's operational progress, financial improvements, and strategic initiatives. Dear Fellow Shareholders, Over the past six months, our stock performance has not fully reflected the progress we have made inside DSS.
